Medico Remedies

{
  "main_header": {
    "sid": 1002925,
    "name": "Medico Remedies",
    "stock_name": "Medico Remedies",
    "full_name": "Medico Remedies Ltd",
    "name_url": "stocks-analysis/medico-remedies",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "41.57",
    "chg": 0.26,
    "chgp": "0.63%",
    "dir": 1,
    "prev_price": "41.31",
    "mcapval": "346.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 540937,
    "symbol": "MEDICO",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE630Y01024",
    "curr_date": "Jun 12, 11:55 AM",
    "curr_time": "11:57 AM",
    "last_traded_at": "Jun 12, 11:55 AM IST",
    "bse_nse_vol": "43.78 k",
    "exc_status": "Active",
    "traded_date": "Jun 12, 2026",
    "traded_date_str": "2026 06 12",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/medico-remedies-1002925-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Medico Remedies Ltd Downgraded to Sell Amid Technical Weakness and Growth Concerns",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/medico-remedies-ltd-downgraded-to-sell-amid-technical-weakness-and-growth-concerns-4048474",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/MedicoRemediesL_mojoScore_4048474.png",
        "date": "2026-06-12 08:19:14",
        "description": "Medico Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 11 June 2026. This shift reflects a combination of deteriorating technical indicators, tempered long-term growth prospects, and valuation concerns despite recent positive quarterly financial results."
      },
      {
        "title": "Medico Remedies Ltd is Rated Hold by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/medico-remedies-ltd-is-rated-hold-by-marketsmojo-4025951",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/6/MedicoRemediesL_mojoScore_4025951.png",
        "date": "2026-06-01 10:10:51",
        "description": "Medico Remedies Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 June 2026, providing investors with an up-to-date perspective on the company’s performance and outlook."
      },
      {
        "title": "Are Medico Remedies Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-medico-remedies-ltd-latest-results-good-or-bad-4007117",
        "imagepath": "",
        "date": "2026-05-22 19:28:43",
        "description": "Medico Remedies Ltd's latest financial results for the quarter ending March 2026 present a mixed operational narrative. The company reported a record net sales figure of ₹56.81 crores, reflecting a year-on-year growth of 37.55% compared to ₹41.30 crores in the same quarter last year. This indicates strong demand and sales momentum. Additionally, the net profit after tax surged to ₹5.86 crores, marking a year-on-year increase of 35.02%, which is a notable achievement.\n\nHowever, when examining the sequential performance, the results reveal some challenges. Revenue declined by 3.19% from the previous quarter's ₹58.68 crores, suggesting potential fluctuations in order execution or seasonal demand variations. Furthermore, the operating margin contracted to 12.59%, down from 16.15% in the same quarter last year, indicating volatility in profitability.\n\nThe company's return on equity remains robust at 17.35%, show..."
      },
      {
        "title": "Medico Remedies Q4 FY26: Strong Profit Surge Masks Margin Volatility Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/medico-remedies-q4-fy26-strong-profit-surge-masks-margin-volatility-concerns-4005245",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/MedicoRemedies_quaterlyResult_4005245.png",
        "date": "2026-05-22 09:54:37",
        "description": "Medico Remedies Ltd., a micro-cap pharmaceutical manufacturer, delivered a robust performance in Q4 FY26 (January-March 2026) with net profit surging 35.02% year-on-year to ₹5.86 crores, marking the company's strongest quarterly earnings to date. However, the quarter-on-quarter decline of 3.19% in revenue and persistent margin volatility have raised questions about the sustainability of this growth trajectory for the ₹389.69 crore market capitalisation company."
      },
      {
        "title": "Medico Remedies Ltd is Rated Hold by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/medico-remedies-ltd-is-rated-hold-by-marketsmojo-4002691",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/MedicoRemediesL_mojoScore_4002691.png",
        "date": "2026-05-21 10:10:58",
        "description": "Medico Remedies Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 21 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing."
      },
      {
        "title": "Medico Remedies Ltd is Rated Hold by MarketsMOJO",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/medico-remedies-ltd-is-rated-hold-by-marketsmojo-3983935",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/MedicoRemediesL_mojoScore_3983935.png",
        "date": "2026-05-10 10:10:37",
        "description": "Medico Remedies Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 May 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "Medico Remedies Ltd Downgraded to Sell Amid Bearish Technicals and Underperformance",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/medico-remedies-ltd-downgraded-to-sell-amid-bearish-technicals-and-underperformance-3967673",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/MedicoRemediesL_mojoScore_3967673.png",
        "date": "2026-04-29 08:24:39",
        "description": "Medico Remedies Ltd has seen its investment rating downgraded from Hold to Sell as of 28 Apr 2026, driven primarily by deteriorating technical indicators despite some positive financial trends. The micro-cap pharmaceutical company’s current Mojo Score stands at 47.0, reflecting a cautious outlook amid mixed signals across quality, valuation, financial trend, and technical parameters."
      },
      {
        "title": "Medico Remedies Ltd Upgraded to Hold as Technicals Improve and Financials Strengthen",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/medico-remedies-ltd-upgraded-to-hold-as-technicals-improve-and-financials-strengthen-3958593",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/MedicoRemediesL_mojoScore_3958593.png",
        "date": "2026-04-23 08:23:40",
        "description": "Medico Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 22 April 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, financial trends, and overall company quality, signalling a cautious but positive outlook for investors amid mixed long-term performance."
      },
      {
        "title": "Medico Remedies Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/medico-remedies-ltd-is-rated-sell-3944503",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/MedicoRemediesL_mojoScore_3944503.png",
        "date": "2026-04-13 10:10:45",
        "description": "Medico Remedies Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 April 2026, providing investors with the most up-to-date view of the company’s performance and outlook."
      }
    ],
    "total": 188,
    "sid": "1002925",
    "stock_news_url": "https://www.marketsmojo.com/news/medico-remedies-1002925"
  },
  "announcements": [
    {
      "caption": "Intimation Of Action Taken Or Order Passed By Regulatory Statutory Enforcement Authority Or Judicial Body Under Regulation 30 (Read With Part B Of Schedule III) (Listing Obligations And Disclosure Requirements) Regulations 2015",
      "datetime": "03-Jun-2026",
      "details": "Please find enclosed",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held Today",
      "datetime": "21-May-2026",
      "details": "Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we hereby inform you that the Board of Directors of our Company at their meeting held today i.e. 21st May 2026 has inter alia considered and approved the following: 1. Audited Standalone Financial Results of the Company for the quarter ended 31st March 2026 and Audited Financial Statements for the year ended on 31st March 2026 along with the Auditors Report thereon. We would like to state that M/s. Shah Shroff & Associates Statutory Auditors of the Company have issued audit report with unmodified opinion on the Statements. 2. Boards Report and its annexures Management Discussion Analysis (MDA) and Corporate Governance Report of the Company for the financial year ended on 31st March 2026. We wish to inform you that the Board Meeting commenced today at 5:00 P.M and concluded at 5:25 P.M.",
      "source": "BSE"
    },
    {
      "caption": "Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2",
      "datetime": "21-May-2026",
      "details": "<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Medico Remedies Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L24230MH1994PLC077187</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2025-2026</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>2024-252025-26</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>0</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>0</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>0</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>2024-252025-26</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>VIDHI ANKIT SHAH</td></tr><tr><td>Designation :-</td><td>COMPANY SECRETARY AND COMPLIANCE OFFICER</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>HARESH MEHTA</td></tr> <tr><td>Designation : -</td><td>WHOLE TIME DIRECTOR AND CFO</td></tr></table><div> <br/> Date: 21/05/2026<br/><br/></div>",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Medico Remedies Ltd has announced <strong>2:10</strong> stock split, ex-date: 16 Mar 23",
          "dt": "2023-03-16",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Medico Remedies Ltd has announced <strong>3:1</strong> bonus issue, ex-date: 16 Nov 21",
          "dt": "2021-11-16",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Medico Remedies Ltd Downgraded to Sell Amid Technical Weakness and Growth Concerns

2026-06-12 08:19:14

Medico Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 11 June 2026. This shift reflects a combination of deteriorating technical indicators, tempered long-term growth prospects, and valuation concerns despite recent positive quarterly financial results.

Read full news article

Medico Remedies Ltd is Rated Hold by MarketsMOJO

2026-06-01 10:10:51

Medico Remedies Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 01 June 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Read full news article

Are Medico Remedies Ltd latest results good or bad?

2026-05-22 19:28:43

Medico Remedies Ltd's latest financial results for the quarter ending March 2026 present a mixed operational narrative. The company reported a record net sales figure of ₹56.81 crores, reflecting a year-on-year growth of 37.55% compared to ₹41.30 crores in the same quarter last year. This indicates strong demand and sales momentum. Additionally, the net profit after tax surged to ₹5.86 crores, marking a year-on-year increase of 35.02%, which is a notable achievement. However, when examining the sequential performance, the results reveal some challenges. Revenue declined by 3.19% from the previous quarter's ₹58.68 crores, suggesting potential fluctuations in order execution or seasonal demand variations. Furthermore, the operating margin contracted to 12.59%, down from 16.15% in the same quarter last year, indicating volatility in profitability. The company's return on equity remains robust at 17.35%, show...

Read full news article

Medico Remedies Q4 FY26: Strong Profit Surge Masks Margin Volatility Concerns

2026-05-22 09:54:37

Medico Remedies Ltd., a micro-cap pharmaceutical manufacturer, delivered a robust performance in Q4 FY26 (January-March 2026) with net profit surging 35.02% year-on-year to ₹5.86 crores, marking the company's strongest quarterly earnings to date. However, the quarter-on-quarter decline of 3.19% in revenue and persistent margin volatility have raised questions about the sustainability of this growth trajectory for the ₹389.69 crore market capitalisation company.

Read full news article

Medico Remedies Ltd is Rated Hold by MarketsMOJO

2026-05-21 10:10:58

Medico Remedies Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 May 2026. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 21 May 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Read full news article

Medico Remedies Ltd is Rated Hold by MarketsMOJO

2026-05-10 10:10:37

Medico Remedies Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 04 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 May 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

Medico Remedies Ltd Downgraded to Sell Amid Bearish Technicals and Underperformance

2026-04-29 08:24:39

Medico Remedies Ltd has seen its investment rating downgraded from Hold to Sell as of 28 Apr 2026, driven primarily by deteriorating technical indicators despite some positive financial trends. The micro-cap pharmaceutical company’s current Mojo Score stands at 47.0, reflecting a cautious outlook amid mixed signals across quality, valuation, financial trend, and technical parameters.

Read full news article

Medico Remedies Ltd Upgraded to Hold as Technicals Improve and Financials Strengthen

2026-04-23 08:23:40

Medico Remedies Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 22 April 2026. This change reflects a nuanced improvement across technical indicators, valuation metrics, financial trends, and overall company quality, signalling a cautious but positive outlook for investors amid mixed long-term performance.

Read full news article

Medico Remedies Ltd is Rated Sell

2026-04-13 10:10:45

Medico Remedies Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 01 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 April 2026, providing investors with the most up-to-date view of the company’s performance and outlook.

Read full news article

View All News